v204295_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

Wednesday, December 1, 2010 BiopharmaWatch Research 1 min read

Key Takeaway: v204295_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Cash runway

~30 mo

Low dilution risk

Lead asset

CytoSorb

Phase 3 · Elective Cardiac Surgical Interventions

v204295_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing